2026-05-30T12:44:52Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/328222026-02-03T11:26:30Zcom_10630_2254col_10630_37953

Mates-Sánchez, José Manuel di Paola, Floriana J. Campos-Sandoval, José Ángel Mazurek, Sybille Márquez-Gómez, Javier 2024-09-23T09:20:11Z 2024-09-23T09:20:11Z 2020-02 José M. Matés, Floriana J. Di Paola, José A. Campos-Sandoval, Sybille Mazurek, Javier Márquez, Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer, Seminars in Cell & Developmental Biology, Volume 98, 2020, Pages 34-43, ISSN 1084-9521, https://doi.org/10.1016/j.semcdb.2019.05.012. (https://www.sciencedirect.com/science/article/pii/S1084952119300734) https://hdl.handle.net/10630/32822 10.1016/j.semcdb.2019.05.012 Metabolic reprogramming in cancer targets glutamine metabolism as a key mechanism to provide energy, biosynthetic precursors and redox requirements to allow the massive proliferation of tumor cells. Glutamine is also a signaling molecule involved in essential pathways regulated by oncogenes and tumor suppressor factors. Glutaminase isoenzymes are critical proteins to control glutaminolysis, a key metabolic pathway for cell proliferation and survival that directs neoplasms’ fate. Adaptive glutamine metabolism can be altered by different metabolic therapies, including the use of specific allosteric inhibitors of glutaminase that can evoke synergistic effects for the therapy of cancer patients. We also review other clinical applications of in vivo assessment of glutaminolysis by metabolomic approaches, including diagnosis and monitoring of cancer. eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Cáncer Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer journal article